ArticleAntiviral research2022
A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera.
Article in Antiviral research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 61 citations in OpenAlex.
- Decoding the human CD4Cell reports. Medicine · 2026Article
- Circular RNA vaccines encoding fusion proteins of Mpox Virus A35R-M1R and B6R-A29L induce robust and durable protective immunity in mice.Journal of nanobiotechnology · 2026Article
- Circular RNA as a New Vaccine Platform: Considerations, Challenges, and Perspectives.Vaccines · 2026Review
- Cavity-Filling Mutations as a Strategy to Stabilize Prefusion Viral Fusion Proteins for Vaccine Design.Computational and structural biotechnology journal · 2026Review
- The regulatory mechanisms and translational applications of non-coding RNA in SARS-CoV-2 infection-related cardiovascular pathology.Frontiers in cardiovascular medicine · 2026Review
- Unveiling the Role of circRNAs in Pyroptotic Signalling: From Molecular Crosstalk to Disease Modulation.Journal of cellular and molecular medicine · 2025Review
- Comparison of immunogenicity and protection efficacy of self-amplifying and circular mRNA vaccines against SARS-CoV-2.iScience · 2025Article
- Review
- Replacing protruding domains of MrNV virus-like particles with sialic acid binding domains enhances binding to SARS-CoV-2 susceptible cells and reduces pseudovirus infection.Scientific reports · 2025Article
- Rational Design and Immunological Mechanisms of Circular RNA-Based Vaccines: Emerging Frontiers in Combating Pathogen Infection.Vaccines · 2025Review
- Coding circular RNA in human cancer.Genes & diseases · 2025Review
- The therapeutic potential of circular RNAs.Nature reviews. Genetics · 2025Review
- The Application of Non-Coding RNAs as Biomarkers, Therapies, and Novel Vaccines in Diseases.International journal of molecular sciences · 2025Review
- Exploring precision treatments in immune-mediated inflammatory diseases: Harnessing the infinite potential of nucleic acid delivery.Exploration (Beijing, China) · 2025Review
- Expanding the Potential of Circular RNA (CircRNA) Vaccines: A Promising Therapeutic Approach.International journal of molecular sciences · 2025Review
- CircSMAD3 represses VSMC phenotype switching and neointima formation via promoting hnRNPA1 ubiquitination degradation.Cell proliferation · 2025Article
- Challenges and Future Prospectives in Circular RNA Investigation.Advances in experimental medicine and biology · 2025Review
- Particulate matter exposure potentiates SARS-CoV-2 delta variant infection by suppressing epithelial antiviral responses.Frontiers in cellular and infection microbiology · 2025Article
- Circular mRNA-LNP vaccine encoding self-assembled E2-TMD-mi3 nanoparticles licit enhanced CSFV-specific immunity over commercial subunit vaccine.Frontiers in immunology · 2025Article
- Circular RNA in hepatocellular carcinoma: emerging therapeutic strategies.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 2 countries.
Funding
Abstract
Next-generation COVID-19 vaccines are critical due to the ongoing evolution of SARS-CoV-2 virus and rapid waning duration of the neutralizing antibody response against current vaccines. The mRNA vaccines mRNA-1273 and BNT162b2 were developed using linear transcripts encoding the prefusion-stabilized trimers (S-2P) of the wildtype spike, which have shown a reduced neutralizing activity against the variants of concern B.1.617.2 and B.1.1.529. Recently, a new version of spike trimer, termed VFLIP (five (V) prolines, Flexibly-Linked, Inter-Protomer disulfide) was developed. Based on the original amino acid sequence of the wildtype spike, VFLIP was genetically engineered by using five proline substitutions, a flexible cleavage site amino acid linker, and an inter-protomer disulfide bond. It has been suggested to possess native-like glycosylation, and greater pre-fusion trimeric stability as opposed to S-2P. Here, we report that the spike protein VFLIP-X, containing six rationally substituted amino acids to reflect emerging variants (K417N, L452R, T478K, E484K, N501Y and D614G), offers a promising candidate for a next-generation SARS-CoV-2 vaccine. Mice immunized by a circular mRNA (circRNA) vaccine prototype producing VFLIP-X had detectable neutralizing antibody titers for up to 7 weeks post-boost against SARS-CoV-2 variants of concern (VOCs) and variants of interest (VOIs). In addition, a balance in T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.